PARIS, FRANCE, 06 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global
specialty-driven biopharmaceutical company, announced today the appointment of
Josep Catllà as EVP, Chief Corporate Affairs Officer, effective August
19, 2024. He will serve on the Executive Leadership Team (ELT) and report
directly to Ipsen's Chief Executive Officer (CEO), David Loew.
"We are thrilled to welcome Josep to Ipsen as our new Chief Corporate Affairs
Officer, as h. He brings years of experience inof communications and public
affairs and a proven track record of developing corporate affairs leaders. His
focus on patient care and sustainability and his strategic vision will be
instrumental to fosterin fostering employee engagement and partnership with
stakeholders while reinforcing Ipsen's culture of collaboration and excellence,"
said David Loew, CEO, Ipsen.
Josep joins Ipsen from Sanofi, where he has spent the last 14 years in
leadership positions at country, region and corporate levels. Over the last four
years he has been serving in a similar position, served as Head of Corporate
Affairs, reporting to Sanofi's CEO. In addition to running Communications and
Public Affairs, he built a robust sustainability strategy.
Josep brings 30 years of experience in the world of communications and public
affairs and government relations, starting his career at the European Commission
in Brussels in the early 1990s and leading the European Public Affairs practice
of Weber Shandwick in Brussels, and then running Weber Shandwick Spain & and
Portugal, before joining the pharmaceutical industry.
"I am incredibly excited to join Ipsen's Executive Leadership Team and to lead
the corporate affairs function as Ipsen continues to deliver innovative
medicines to patients around the world. I am encouraged by the transformation
and evolution of the company, building on their long history and legacy. I look
forward to working with patient communities and alongside policymakers, media,
and other partners to deliver on Ipsen'´s mission on a sustainable manner, while
embarking our employees into this fascinating journey of improving people´s
lives," said Josep Catllà.
Gwenan White, EVP, Communications, External Affairs & Sustainability for the
last three years, will leave Ipsen to pursue other opportunities. The Company
wishes Gwenan every success in her future endeavors and would like to thank her
for her leadership.
ENDS
About Ipsen
We are a global biopharmaceutical company with a focus on bringing
transformative medicines to patients in three therapeutic areas: Oncology, Rare
Disease and Neuroscience.
Our pipeline is fueled by external innovation and supported by nearly 100 years
of development experience and global hubs in the U.S., France and the U.K. Our
teams in more than 40 countries and our partnerships around the world enable us
to bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored
Level I American Depositary Receipt program (ADR: IPSEY). For more information,
visit ipsen.com.
Ipsen contacts
Investors
* Craig Marks | craig.marks@ipsen.com
* Nicolas Bolger | nicolas.bogler@ipsen.com
Media
* Amy Wolf | amy.wolf@ipsen.com
* Ioana Piscociu | ioana.piscociu@ipsen.com
Disclaimers and/or Forward-Looking Statements
The forward-looking statements, objectives and targets contained herein are
based on Ipsen's management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect Ipsen's future ability
to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today. Use of the
words 'believes', 'anticipates' and 'expects' and similar expressions are
intended to identify forward-looking statements, including Ipsen's expectations
regarding future events, including regulatory filings and determinations.
Moreover, the targets described in this document were prepared without taking
into account external-growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend on conditions
or facts likely to happen in the future, and not exclusively on historical data.
Actual results may depart significantly from these targets given the occurrence
of certain risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being launched on
the market or reaching its commercial targets, notably for regulatory or
competition reasons. Ipsen must face or might face competition from generic
medicine that might translate into a loss of market share. Furthermore, the
research and development process involves several stages each of which involves
the substantial risk that Ipsen may fail to achieve its objectives and be forced
to abandon its efforts with regards to a medicine in which it has invested
significant sums. Therefore, Ipsen cannot be certain that favorable results
obtained during preclinical trials will be confirmed subsequently during
clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the medicine concerned. There can
be no guarantees a medicine will receive the necessary regulatory approvals or
that the medicine will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking
statements. Other risks and uncertainties include but are not limited to,
general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation; global trends
toward healthcare cost containment; technological advances, new medicine and
patents attained by competitors; challenges inherent in new-medicine
development, including obtaining regulatory approval; Ipsen's ability to
accurately predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of Ipsen's patents and other protections for
innovative medicines; and the exposure to litigation, including patent
litigation, and/or regulatory actions. Ipsen also depends on third parties to
develop and market some of its medicines which could potentially generate
substantial royalties; these partners could behave in such ways which could
cause damage to Ipsen's activities and financial results. Ipsen cannot be
certain that its partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of Ipsen's partners
could generate lower revenues than expected. Such situations could have a
negative impact on Ipsen's business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or revise any
forward-looking statements, targets or estimates contained in this press release
to reflect any change in events, conditions, assumptions or circumstances on
which any such statements are based, unless so required by applicable law.
Ipsen's business is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers. The risks and
uncertainties set out are not exhaustive and the reader is advised to refer to
Ipsen's latest Universal Registration Document, available on ipsen.com
(https://www.globenewswire.com/Tracker?data=cRbeTYiLm_i554EQ7ITgGkjFSkEO7CuADsdG
INJYRhuLZP1b2RRGQKaNMQhqDBefwdyOcUcRf2VYKHI9RWUEWA==).
Â